These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1423 related articles for article (PubMed ID: 26833159)
1. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci. Smith JR; Yim J; Raut A; Rybak MJ Antimicrob Agents Chemother; 2016 Apr; 60(4):2352-8. PubMed ID: 26833159 [TBL] [Abstract][Full Text] [Related]
2. β-Lactam Combinations with Vancomycin Show Synergistic Activity against Vancomycin-Susceptible Staphylococcus aureus, Vancomycin-Intermediate S. aureus (VISA), and Heterogeneous VISA. Tran N; Rybak MJ Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29555635 [TBL] [Abstract][Full Text] [Related]
3. β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium. Smith JR; Barber KE; Raut A; Aboutaleb M; Sakoulas G; Rybak MJ J Antimicrob Chemother; 2015; 70(6):1738-43. PubMed ID: 25645208 [TBL] [Abstract][Full Text] [Related]
4. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269 [TBL] [Abstract][Full Text] [Related]
5. In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus (HA-MRSA) isolates. Vidaillac C; Leonard SN; Rybak MJ Int J Antimicrob Agents; 2010 Jun; 35(6):527-30. PubMed ID: 20346632 [TBL] [Abstract][Full Text] [Related]
7. The Prevalence of Vancomycin-Intermediate Staphylococcus aureus and Heterogeneous VISA Among Methicillin-Resistant Strains Isolated from Pediatric Population in a Turkish University Hospital. Mirza HC; Sancak B; Gür D Microb Drug Resist; 2015 Oct; 21(5):537-44. PubMed ID: 25919019 [TBL] [Abstract][Full Text] [Related]
8. Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models. Smith JR; Barber KE; Hallesy J; Raut A; Rybak MJ Antimicrob Agents Chemother; 2015 Sep; 59(9):5529-34. PubMed ID: 26124162 [TBL] [Abstract][Full Text] [Related]
9. β-Lactams enhance daptomycin activity against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium in in vitro pharmacokinetic/pharmacodynamic models. Smith JR; Barber KE; Raut A; Rybak MJ Antimicrob Agents Chemother; 2015 May; 59(5):2842-8. PubMed ID: 25753639 [TBL] [Abstract][Full Text] [Related]
10. Dalbavancin Alone and in Combination with Ceftaroline against Four Different Phenotypes of Kebriaei R; Rice SA; Stamper KC; Rybak MJ Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670436 [TBL] [Abstract][Full Text] [Related]
11. In vitro time-kill analysis of oritavancin against clinical isolates of methicillin-resistant Staphylococcus aureus with reduced susceptibility to daptomycin. Vidaillac C; Parra-Ruiz J; Rybak MJ Diagn Microbiol Infect Dis; 2011 Dec; 71(4):470-3. PubMed ID: 22018937 [TBL] [Abstract][Full Text] [Related]
12. Comparative activity of oritavancin against meticillin-resistant Staphylococcus aureus (MRSA) bloodstream isolates from Geneva University Hospital. Vaudaux P; Huggler E; Arhin FF; Moeck G; Renzoni A; Lew DP Int J Antimicrob Agents; 2009 Dec; 34(6):540-3. PubMed ID: 19744838 [TBL] [Abstract][Full Text] [Related]
13. Potent synergy of ceftobiprole plus daptomycin against multiple strains of Staphylococcus aureus with various resistance phenotypes. Barber KE; Werth BJ; Ireland CE; Stone NE; Nonejuie P; Sakoulas G; Pogliano J; Rybak MJ J Antimicrob Chemother; 2014 Nov; 69(11):3006-10. PubMed ID: 24990867 [TBL] [Abstract][Full Text] [Related]
14. A combination of ceftaroline and daptomycin has synergistic and bactericidal activity in vitro against daptomycin nonsusceptible methicillin-resistant Staphylococcus aureus (MRSA). Shafiq I; Bulman ZP; Spitznogle SL; Osorio JE; Reilly IS; Lesse AJ; Parameswaran GI; Mergenhagen KA; Tsuji BT Infect Dis (Lond); 2017 May; 49(5):410-416. PubMed ID: 28116950 [TBL] [Abstract][Full Text] [Related]
15. In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014. Biedenbach DJ; Arhin FF; Moeck G; Lynch TF; Sahm DF Int J Antimicrob Agents; 2015 Dec; 46(6):674-81. PubMed ID: 26541881 [TBL] [Abstract][Full Text] [Related]
16. In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure. Bhalodi AA; Hagihara M; Nicolau DP; Kuti JL Antimicrob Agents Chemother; 2014; 58(2):672-7. PubMed ID: 24217694 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid. Barber KE; Smith JR; Raut A; Rybak MJ J Antimicrob Chemother; 2016 Jan; 71(1):152-5. PubMed ID: 26476277 [TBL] [Abstract][Full Text] [Related]
18. In vitro activity of oritavancin alone or in combination against vancomycin-susceptible and -resistant enterococci. Wu T; Meyer K; Harrington AT; Danziger LH; Wenzler E J Antimicrob Chemother; 2019 May; 74(5):1300-1305. PubMed ID: 30753495 [TBL] [Abstract][Full Text] [Related]
19. In vitro activities of oritavancin and comparators against meticillin-resistant Staphylococcus aureus (MRSA) isolates harbouring the novel mecC gene. Arhin FF; Sarmiento I; Moeck G Int J Antimicrob Agents; 2014 Jul; 44(1):65-8. PubMed ID: 24906505 [TBL] [Abstract][Full Text] [Related]
20. [In vitro activity of daptomycin against VRE and MRSA strains]. Aktaş G; Derbentli S Mikrobiyol Bul; 2014 Jan; 48(1):123-8. PubMed ID: 24506722 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]